General Information of DTT (ID: TTT402Y)

DTT Name Stimulator of interferon genes protein (TMEM173) DTT Info
Gene Name TMEM173

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
15 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
ADU- S100 DMM6B2Y Head and neck cancer 2D42 Phase 2 [1]
ADU-S100 DM8HBUI Head and neck cancer 2D42 Phase 2 [2]
MK-1454 DMEDITW Squamous head and neck cell carcinom 2D60.0 Phase 2 [3]
IMSA101 DM43ICH Solid tumour/cancer 2A00-2F9Z Phase 1/2 [4]
A296 DMY4DUY Aggressive cancer 2A00-2F9Z Phase 1 [5]
BMS-986301 DMM3DBU Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
E7766 DM8TU5R Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
GSK3745417 DMRYNJD Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
MK-2118 DMKNH8B Lymphoma 2A80-2A86 Phase 1 [9]
SB 11285 DMZ9YWG Head-neck squamous cell carcinoma 2D60.0 Phase 1 [10]
SNX281 DMCGPU8 Lymphoma 2A80-2A86 Phase 1 [11]
SYNB1891 DMZJNHM Lymphoma 2A80-2A86 Phase 1 [12]
TAK-500 DMVZ2FG Aggressive cancer 2A00-2F9Z Phase 1 [13]
TAK-676 DMCKF5J Solid tumour/cancer 2A00-2F9Z Phase 1 [14]
XMT-2056 DM904CF Aggressive cancer 2A00-2F9Z Phase 1 [15]
------------------------------------------------------------------------------------
⏷ Show the Full List of 15 Clinical Trial Drug(s)
2 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
C-176 DMKGSRZ Aicardi-Goutieres syndrome 5C55.2 Investigative [16]
C-178 DM4FEU8 Aicardi-Goutieres syndrome 5C55.2 Investigative [17]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 Magnitude of Therapeutic STING Activation Determines CD8 + T Cell-Mediated Anti-tumor Immunity. Cell Rep. 2018 Dec 11;25(11):3074-3085.e5.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 National Cancer Institute Drug Dictionary (drug name MK1454).
4 Clinical pipeline report, company report or official report of ImmuneSensor Therapeutics.
5 Clinical pipeline report, company report or official report of Klus Pharma
6 Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy. J Clin Med. 2020 Oct 16;9(10):3323.
7 E7766, a Macrocycle-Bridged Stimulator of Interferon Genes (STING) Agonist with Potent Pan-Genotypic Activity. ChemMedChem. 2021 Jun 7;16(11):1740-1743.
8 National Cancer Institute Drug Dictionary (drug name GSK3745417).
9 National Cancer Institute Drug Dictionary (drug name ML2118).
10 Clinical pipeline report, company report or official report of F-star Therapeutics.
11 Clinical pipeline report, company report or official report of Silicon Therapeutics.
12 Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Nat Commun. 2020 Jun 1;11(1):2739.
13 ClinicalTrials.gov (NCT05070247) An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
14 National Cancer Institute Drug Dictionary (drug name TAK676).
15 Clinical pipeline report, company report or official report of GlaxoSmithKline
16 Stimulator of IFN genes mediates neuroinflammatory injury by suppressing AMPK signal in experimental subarachnoid hemorrhage. J Neuroinflammation. 2020 May 25;17(1):165.
17 Targeting STING with covalent small-molecule inhibitors. Nature. 2018 Jul;559(7713):269-273.